How to Get Rezdiffra (Resmetirom) in North Carolina

Direct answer

Resmetirom (brand name Rezdiffra) is a thyroid hormone receptor beta (THR-beta) agonist tablet, FDA-approved in March 2024 for adults with MASH and biopsy-confirmed or non-invasively staged fibrosis F2 or F3, used together with diet and exercise. It is not approved for earlier-stage fatty liver disease (simple steatosis or F0-F1 fibrosis) or for decompensated cirrhosis. North Carolina patients obtain it the same way patients in most states do: through a prescriber (in person or via telehealth) who documents a qualifying MASH diagnosis and fibrosis stage, followed by insurer prior authorization and dispensing through a specialty pharmacy. The clinical eligibility criteria come from the FDA label and are stable; the insurance, pharmacy, and pricing mechanics are not, and should be reconfirmed at the time a patient actually tries to fill the prescription.

What Rezdiffra is, and what it is not

Resmetirom is distinct from other liver-directed and metabolic drugs sometimes discussed alongside it (GLP-1 agonists, vitamin E, pioglitazone). It is the first drug specifically approved for MASH rather than for a related metabolic condition. It works by selectively activating THR-beta in the liver, which is intended to avoid the cardiac and bone effects seen with older, non-selective thyroid hormone analogs that failed in earlier development programs.

Resmetirom's approval covers noncirrhotic MASH with moderate-to-advanced fibrosis (F2-F3). It is contraindicated in decompensated cirrhosis (Child-Pugh B or C), and its use in compensated cirrhosis (F4) has narrower evidentiary support than its use in F2-F3 disease. A prescriber unfamiliar with fibrosis staging is the most common practical bottleneck to getting an appropriate prescription, not licensure type.

Liver disease is common nationally. The CDC tracks chronic liver disease and cirrhosis prevalence at the national level (CDC FastStats), but that page does not break prevalence out by state, and this article does not have a verified North Carolina-specific prevalence figure. Any claim about how many North Carolinians have MASH specifically should be treated as an estimate pending a state-level source, not a precise number.

What the trial evidence shows, and what it doesn't

Resmetirom's approval rests on the MAESTRO clinical trial program, a multicenter phase 3 randomized, placebo-controlled effort designed to evaluate histologic and biochemical endpoints in biopsy-confirmed MASH (MAESTRO program design). The program reported that resmetirom produced significantly higher rates of MASH resolution without worsening fibrosis, and higher rates of at least one-stage fibrosis improvement, compared with placebo at 52 weeks. A practical clinical review published after approval summarizes the drug's efficacy signal, safety profile, and prescribing considerations for practicing clinicians (practical perspective on resmetirom).

This article does not carry forward exact response-rate percentages, LDL reduction figures, or adverse-event rates from the original trial publication, because those numbers require verification directly against the primary New England Journal of Medicine publication or the current FDA label rather than a secondary summary. A clinician writing the actual prescription should confirm current efficacy and safety numbers from the label at accessdata.fda.gov before counseling a patient on expected outcomes.

Reported adverse effects in the trial program included gastrointestinal symptoms (diarrhea and nausea were more common with resmetirom than placebo) and a modest increase in gallbladder-related events. These were generally described as mild to moderate. Patients with pre-existing gallstones or a history of biliary disease should discuss this risk with their prescriber specifically, and dose adjustment or discontinuation triggers (such as a defined rise in ALT) belong in the individualized conversation with the prescriber, not in a general access guide.

Other liver-directed agents, including repurposed thyroid hormone approaches, remain under investigation for MASH and are not FDA-approved; a 2026 review calling for randomized trials of levothyroxine in MASH illustrates that resmetirom is not the only THR-pathway strategy being studied, and that unapproved alternatives should not be substituted for it outside a trial (levothyroxine RCT rationale, 2026).

Evidence-boundary statement: It is established that resmetirom is FDA-approved for noncirrhotic MASH with F2-F3 fibrosis and that its approval was based on histologic endpoints in a randomized trial program. It is plausible but not established at the level of long-term outcomes data that resmetirom prevents progression to cirrhosis, liver transplant, or liver-related death, since the pivotal trials measured surrogate histologic and biochemical endpoints, not those hard outcomes, over the studied timeframe. It is not established that resmetirom is appropriate for MASH without documented moderate-to-advanced fibrosis, for decompensated cirrhosis, or as a substitute for weight loss and metabolic risk-factor treatment.

Who can prescribe it in North Carolina

Physicians (MD, DO), nurse practitioners, and physician assistants with active prescriptive authority in North Carolina can prescribe Rezdiffra within their scope of practice and any required supervision or collaboration arrangements. Hepatologists and gastroenterologists most commonly manage MASH staging and treatment, but endocrinologists and primary care clinicians experienced with metabolic liver disease also prescribe it. North Carolina has multiple academic and community gastroenterology and hepatology practices; whether a specific practice currently offers Rezdiffra evaluation and how quickly it can schedule a new patient changes over time and should be confirmed directly with the practice.

A prescriber typically wants at least one of the following before writing the prescription:

• A liver biopsy showing MASH with fibrosis stage F2 or F3
• A FibroScan (vibration-controlled transient elastography) result consistent with significant fibrosis, combined with an Enhanced Liver Fibrosis (ELF) score in the elevated range
• A FIB-4 index in the higher-risk range, confirmed with imaging or a validated biomarker panel

Non-invasive testing is increasingly accepted as first-line fibrosis assessment in clinical practice guidance, and most insurers now accept validated non-invasive scores for prior authorization rather than requiring biopsy in every case. The exact FibroScan and ELF cutoffs an individual insurer will accept are a plan-level rule, not a fixed clinical fact, and should be confirmed with that plan before ordering additional testing.

Telehealth access in North Carolina

Telehealth prescribing of non-controlled medications, including Rezdiffra, is generally permitted in North Carolina when the prescriber holds an active North Carolina license (or a qualifying interstate compact license) and conducts an appropriate evaluation. North Carolina does not require an in-person visit before prescribing a non-controlled substance like resmetirom, but the specific telehealth parity and reimbursement rules that apply to a given insurance plan can change and should be confirmed rather than assumed from this article.

A telehealth visit can review existing labs, imaging, and fibrosis staging and result in a prescription sent electronically to the patient's chosen pharmacy. What telehealth cannot do is perform a FibroScan remotely. A patient without a prior elastography result will need to visit a local facility, hospital-affiliated GI clinic, or imaging center for that test before or after the telehealth visit, then return with results.

Labs and testing before starting treatment

Standard pre-treatment evaluation generally includes:

• Liver function tests: ALT, AST, alkaline phosphatase, total bilirubin, and albumin
• Thyroid function: TSH and free T4 at baseline, useful for interpreting any subsequent thyroid-related lab changes even though THR-beta selectivity is intended to limit systemic thyroid effects
• Lipid panel: total cholesterol, LDL, HDL, and triglycerides
• CBC and basic metabolic panel as general safety baselines
• Fibrosis assessment: FibroScan, ELF score, FIB-4 index, or biopsy

Follow-up monitoring during treatment, including the frequency of liver function testing and the ALT threshold that should prompt discontinuation, is specified in the FDA label and should be confirmed there rather than assumed from a summary article, since label updates can change monitoring recommendations. This is individualized clinical guidance that belongs in the conversation between patient and prescriber, not a substitute for it.

Prior authorization and insurance in North Carolina

Rezdiffra is a specialty tier medication, and prior authorization is close to universal across commercial insurers because of its cost. Typical PA documentation across insurers generally includes a confirmed MASH diagnosis, fibrosis staging by biopsy or a validated non-invasive test, baseline liver labs, and sometimes documentation of a prior lifestyle-modification attempt. The exact combination of requirements, and how long a review takes, is plan-specific and changes over time; it should be pulled from the current insurer medical policy rather than treated as fixed.

North Carolina Medicaid managed care coverage for the MASH indication specifically is not addressed by a source verified for this article and should be confirmed directly with the patient's Medicaid managed care organization before counting on coverage.

Manufacturer copay assistance and patient assistance programs exist for many specialty drugs, including reportedly for Rezdiffra, but this article does not have a verified, current description of program eligibility, savings amount, or income limits. Confirm current program terms directly with the manufacturer or the prescriber's office rather than relying on a fixed dollar figure from any secondary source, since these terms change.

List price for Rezdiffra has been reported in secondary sources as being in the range of tens of thousands of dollars annually. This article does not carry forward a precise dollar figure as fact, because list prices change and the number that matters to an individual patient is their out-of-pocket cost after insurance and any assistance program, not the list price.

Pharmacy access

Rezdiffra is typically dispensed through specialty pharmacies rather than standard retail pharmacies, because of its specialty tier status and the coordination needed with prior authorization. Which specific specialty pharmacy network a patient uses is generally dictated by their insurance plan, not by the patient's or prescriber's preference.

503A compounding pharmacies in North Carolina may prepare a patient-specific resmetirom formulation only when legal, prescription, sourcing, and documented clinical-need requirements are met, for example when a patient cannot use the commercially available tablet strengths. Compounding is not a routine substitute for the FDA-approved product and whether any specific North Carolina pharmacy currently offers it should be confirmed directly with that pharmacy.

Transferring a prescription into North Carolina

A pharmacy can generally transfer a non-controlled prescription like Rezdiffra to a North Carolina location, subject to standard verification between pharmacies. If a patient's insurance changes as part of a move, a new prior authorization under the new plan is the most common source of delay, so starting that process a few weeks before the existing supply runs out is reasonable. An out-of-state telehealth prescriber must hold valid North Carolina licensure (or a qualifying compact license) to continue prescribing for a North Carolina resident; if they do not, the patient needs to establish care with a properly licensed in-state or telehealth provider.

When to seek urgent care instead

Resmetirom is not an emergency medication, and delays in starting it are not themselves a medical emergency. Patients on resmetirom (or being evaluated for it) should seek urgent medical attention for jaundice, severe abdominal pain, dark urine, unexplained bruising or bleeding, or signs of decompensated liver disease such as confusion or abdominal swelling. Any of these findings should be evaluated promptly rather than addressed through a routine telehealth or access workflow.

Verification checklist: what is stable versus what you must reconfirm

Use this before assuming any fact in this article still applies at the time you act on it.

Stable facts (federal approval and core clinical criteria; unlikely to change without a formal FDA or guideline update):

• Resmetirom (Rezdiffra) received FDA accelerated approval in March 2024 for noncirrhotic MASH with fibrosis stage F2-F3, used with diet and exercise
• It is contraindicated in decompensated cirrhosis
• It is dosed once daily, with dose based on body weight, per the current FDA label
• Fibrosis staging (biopsy, FibroScan, ELF, FIB-4) is the clinical basis for eligibility, not diagnosis of MASH alone

Date-sensitive facts you must reconfirm before relying on them (check the source directly and note the date you checked):

• Whether your specific commercial plan or North Carolina Medicaid managed care organization covers Rezdiffra for MASH, and its current prior authorization criteria
• How long prior authorization review currently takes with your specific insurer
• Which specialty pharmacy your plan requires and its current fulfillment timeline
• Current list price, your plan's cost-sharing, and whether a manufacturer copay or patient assistance program applies to your situation and its current terms
• Whether a specific North Carolina prescriber, telehealth platform, or 503A compounding pharmacy currently offers resmetirom evaluation or dispensing
• Current FDA label language on monitoring intervals and discontinuation thresholds, since labels for accelerated-approval drugs can be updated

If a fact from the second list appears anywhere in this article with a specific number, treat that number as illustrative and reconfirm it directly rather than acting on it.